JP2014504598A5 - - Google Patents

Download PDF

Info

Publication number
JP2014504598A5
JP2014504598A5 JP2013549933A JP2013549933A JP2014504598A5 JP 2014504598 A5 JP2014504598 A5 JP 2014504598A5 JP 2013549933 A JP2013549933 A JP 2013549933A JP 2013549933 A JP2013549933 A JP 2013549933A JP 2014504598 A5 JP2014504598 A5 JP 2014504598A5
Authority
JP
Japan
Prior art keywords
group
cys
disease
peptide
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013549933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504598A (ja
JP5943433B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2012/000032 external-priority patent/WO2012098546A2/en
Publication of JP2014504598A publication Critical patent/JP2014504598A/ja
Publication of JP2014504598A5 publication Critical patent/JP2014504598A5/ja
Application granted granted Critical
Publication of JP5943433B2 publication Critical patent/JP5943433B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013549933A 2011-01-20 2012-01-19 抗酸化、抗炎症、抗放射線、金属キレート化合物およびその使用 Expired - Fee Related JP5943433B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161434454P 2011-01-20 2011-01-20
US61/434,454 2011-01-20
US201161469138P 2011-03-30 2011-03-30
US61/469,138 2011-03-30
PCT/IL2012/000032 WO2012098546A2 (en) 2011-01-20 2012-01-19 Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2014504598A JP2014504598A (ja) 2014-02-24
JP2014504598A5 true JP2014504598A5 (enExample) 2015-03-05
JP5943433B2 JP5943433B2 (ja) 2016-07-05

Family

ID=45755445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549933A Expired - Fee Related JP5943433B2 (ja) 2011-01-20 2012-01-19 抗酸化、抗炎症、抗放射線、金属キレート化合物およびその使用

Country Status (8)

Country Link
US (3) US8802635B2 (enExample)
EP (2) EP2665742B1 (enExample)
JP (1) JP5943433B2 (enExample)
CN (2) CN105837659A (enExample)
AU (1) AU2012208283B2 (enExample)
CA (1) CA2825273A1 (enExample)
IN (1) IN2013MN01582A (enExample)
WO (1) WO2012098546A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104717970A (zh) * 2012-07-23 2015-06-17 万德-生物技术及制药有限公司 提高谷胱甘肽的组合物及其用途
EP2877194A4 (en) * 2012-07-25 2016-03-16 Oneday Biotech And Pharma Ltd Compositions and methods for increasing carnitine concentration in muscle tissue
CN103467569B (zh) * 2013-08-10 2015-05-20 李�昊 一种抗菌止痒消炎消肿去疤痕的短肽及其应用
LT3066089T (lt) 2013-11-08 2020-02-25 Promentis Pharmaceuticals, Inc. Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai
EP3077049B1 (en) * 2013-12-02 2019-06-19 Stealth BioTherapeutics Corp Compositions for use in treating vitiligo
WO2015118546A1 (en) * 2014-02-10 2015-08-13 Oneday - Biotech And Pharma Ltd. Mucolytic compositions and uses thereof
US9464111B2 (en) 2014-06-26 2016-10-11 L'oreal Short peptides and a method of use as an antioxidant
JP6742312B2 (ja) * 2014-08-05 2020-08-19 アマンタン・エクスペール 皮膚保護組成物
JP6533723B2 (ja) * 2015-09-11 2019-06-19 キユーピー株式会社 抗酸化剤
CN105254714B (zh) * 2015-10-16 2019-09-10 中国农业大学 一种源自酪蛋白的抗氧化肽及应用
CN106432014B (zh) 2016-09-05 2019-08-16 中国医学科学院放射医学研究所 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用
CN106749525B (zh) * 2016-12-07 2020-01-07 南京财经大学 一种小肽及其应用
KR101943081B1 (ko) * 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
CN111278420B (zh) * 2017-09-18 2023-09-19 安尼根有限公司 活性物质-六肽复合体及包含其的化妆品组合物
CN108484738B (zh) * 2018-03-28 2022-03-15 中国人民解放军军事科学院军事医学研究院 辐抗肽突变蛋白及其制备与纯化方法
WO2021230393A1 (ko) * 2020-05-12 2021-11-18 주식회사 카인사이언스 염증성 피부질환 치료용 펩타이드 및 이의 용도
CN112608966B (zh) * 2020-12-31 2023-05-23 华南理工大学 一种超声辅助矿物质螯合杏仁肽及其制备方法和应用
CN114041603A (zh) * 2021-11-09 2022-02-15 中国农业大学 肽-锌螯合物在抗过敏产品中的应用
EP4554553A1 (en) * 2022-07-13 2025-05-21 L'oreal Modified peptides, composition, method for inhibiting contraction of muscle cells, method for improving the skin and use of a modified peptide
CN115920014A (zh) * 2022-12-08 2023-04-07 酵之美生物科技(绍兴)有限责任公司 硫氧还蛋白的模拟肽的一种治疗炎症性肠病的用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
WO1998000160A1 (en) * 1996-06-28 1998-01-08 Nat Jewish Ct Immun & Respirat USE OF THIOREDOXIN-LIKE MOLECULES FOR INDUCTION OF MnSOD TO TREAT OXIDATIVE DAMAGE
US5928926A (en) * 1996-07-01 1999-07-27 Research Development Foundation Isolation and cloning of the human ARSA-I gene and uses thereof
US5874468A (en) 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US6369106B1 (en) 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US5889055A (en) 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US6627746B1 (en) * 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
AU4411499A (en) 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Connective tissue growth factor-4
US8252309B2 (en) 2000-04-04 2012-08-28 Sigma-Tau Industrie Farmaceutiche Riunite Spa Dietary supplement energy-providing to skeletal muscles
GB2368339B (en) 2000-10-26 2002-09-18 Yissum Res Dev Co Complex incorporating a plurality of antioxidants
US20030109457A1 (en) * 2001-10-25 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
AU2002238106A1 (en) * 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
GB0108491D0 (en) * 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
WO2003088947A1 (en) 2002-04-22 2003-10-30 Experimental & Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
WO2004024868A2 (en) 2002-09-10 2004-03-25 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
JP2007527503A (ja) * 2003-06-17 2007-09-27 プロノタ・エヌブイ ペプチドコンボ及びそれらの使用
ITRM20040066A1 (it) * 2004-02-09 2004-05-09 Consiglio Nazionale Ricerche Metodo di identificazione di peptidi antigenici e relativo uso per la preparazione di un vaccino anti hiv-1.
WO2005123108A2 (en) 2004-06-09 2005-12-29 William Feinstein Advanced vitamins and protein based nutritional supplements
CA2613008C (en) * 2005-06-24 2015-08-25 Regents Of The University Of Minnesota Using cytosine deaminases to diminish retroelement transfer from pigs to humans
WO2007144979A1 (ja) * 2006-06-12 2007-12-21 Vexon, Inc. ペプチド誘導体
US7713937B2 (en) * 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US20090285912A1 (en) 2008-05-16 2009-11-19 Ramiro Rodriquez Food Supplement and Method for Enhancing Athletic Performance
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
CN104717970A (zh) 2012-07-23 2015-06-17 万德-生物技术及制药有限公司 提高谷胱甘肽的组合物及其用途
EP2877194A4 (en) 2012-07-25 2016-03-16 Oneday Biotech And Pharma Ltd Compositions and methods for increasing carnitine concentration in muscle tissue

Similar Documents

Publication Publication Date Title
JP2014504598A5 (enExample)
CY1123749T1 (el) Μεθοδοι μειωσης του κινδυνου καρδιαγγειακου γεγονοτος σε ενα υποκειμενο επι θεραπειας στατινης χρησιμοποιωντας αιθυλ εστερα εικοσαπενταενοϊκου οξεος
ES2613606T3 (es) Uso de derivados de ácidos grasos polinsaturados como medicamentos
HK1204272A1 (en) Methods of treating pediatric metabolic syndrome
CO6341548A2 (es) Nuevos lipidos que contienen azufre para el uso como suplemento alimenticio o como medicamento
NZ596386A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
MX355035B (es) Composición de uridina y citidina para uso en la prevención o tratamiento de neurotrauma.
JP2013515742A5 (enExample)
NZ709083A (en) Eicosapentaenoic acid (epa) formulations
CY1122809T1 (el) Εστερικα προ-φαρμακα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανολης για τη θεραπεια οφθαλμικων νοσηματων
IN2012DN00407A (enExample)
HRP20160203T1 (hr) Pripravci koji sadrže 15-hepe i postupci njihove upotrebe
WO2017077528A3 (en) Methods and pharmaceutical compositions for treatment of lung inflammation
Bazan Neurotrophins induce neuroprotective signaling in the retinal pigment epithelial cell by activating the synthesis nl of the anti-inflammatory and anti-apoptotic neuroprotectin D1
MY145985A (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
JP2019513752A5 (enExample)
JP2019052168A (ja) オメガ−３脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ
MX2011008261A (es) FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1.
JP2010522146A5 (enExample)
JP2016501248A5 (enExample)
JP2019507182A5 (enExample)
WO2014193652A3 (en) Novel n-3 immunoresolvents: structures and actions
JP2004520343A5 (enExample)
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
JP2012513380A5 (enExample)